Virax Biolabs Group Limited Ordinary Shares Stock Prediction
AI-powered sentiment analysis and prediction trends for VRAX, updated each market day.
VRAX AI Sentiment
AI predicts Virax Biolabs Group Limited Ordinary Shares stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Virax Biolabs Group Limited Ordinary Shares
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
Exchange
Market Cap
$1,001,420
Cap Tier
Employees
19
Listed Since
July 21, 2022
Website
VRAX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
VRAX Volatility
Virax Biolabs Group Limited Ordinary Shares has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
